Cargando…

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast

The “endo-symbiotic theory of mitochondrial evolution” states that mitochondrial organelles evolved from engulfed aerobic bacteria, after millions of years of symbiosis and adaptation. Here, we have exploited this premise to design new antibiotics and novel anti-cancer therapies, using a convergent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozsvari, Bela, Fiorillo, Marco, Bonuccelli, Gloria, Cappello, Anna Rita, Frattaruolo, Luca, Sotgia, Federica, Trowbridge, Rachel, Foster, Richard, Lisanti, Michael P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620185/ https://www.ncbi.nlm.nih.gov/pubmed/28978045 http://dx.doi.org/10.18632/oncotarget.19084

Ejemplares similares

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
por: Sotgia, Federica, et al.
Publicado: (2018)

Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2017)

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds
por: Ózsvári, Béla, et al.
Publicado: (2020)

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy
por: Ozsvari, Bela, et al.
Publicado: (2017)

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2018)

Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
por: Bonuccelli, Gloria, et al.
Publicado: (2018)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2019)

“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
por: Fiorillo, Marco, et al.
Publicado: (2019)

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
por: Fiorillo, Marco, et al.
Publicado: (2016)

High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy
por: Fiorillo, Marco, et al.
Publicado: (2021)

Hallmarks of the cancer cell of origin: Comparisons with “energetic” cancer stem cells (e-CSCs)
por: Sotgia, Federica, et al.
Publicado: (2019)

A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
por: Ózsvári, Béla, et al.
Publicado: (2020)

Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2017)

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis
por: Ozsvari, Bela, et al.
Publicado: (2017)

Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)
por: Fiorillo, Marco, et al.
Publicado: (2019)

Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERRα Pathway
por: Brindisi, Matteo, et al.
Publicado: (2020)

Cancer stem cells (CSCs): metabolic strategies for their identification and eradication
por: De Francesco, Ernestina M., et al.
Publicado: (2018)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
por: Bonuccelli, Gloria, et al.
Publicado: (2016)

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito‐stemness and ribo‐stemness features
por: Peiris‐Pagès, Maria, et al.
Publicado: (2019)

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells
por: Lamb, Rebecca, et al.
Publicado: (2015)

Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling
por: Peiris-Pagès, Maria, et al.
Publicado: (2018)

Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
por: Fiorillo, Marco, et al.
Publicado: (2017)

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells
por: De Luca, Arianna, et al.
Publicado: (2015)

Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”
por: Fiorillo, Marco, et al.
Publicado: (2015)

Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2017)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

Azithromycin and Roxithromycin define a new family of “senolytic” drugs that target senescent human fibroblasts
por: Ozsvari, Bela, et al.
Publicado: (2018)

Thioalbamide, A Thioamidated Peptide from Amycolatopsis alba, Affects Tumor Growth and Stemness by Inducing Metabolic Dysfunction and Oxidative Stress
por: Frattaruolo, Luca, et al.
Publicado: (2019)

Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling
por: Lamb, Rebecca, et al.
Publicado: (2015)

MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity In Vivo
por: Sargiacomo, Camillo, et al.
Publicado: (2021)

Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study
por: Scatena, Cristian, et al.
Publicado: (2018)

Antibiotics that target mitochondria extend lifespan in C. elegans
por: Bonuccelli, Gloria, et al.
Publicado: (2023)

Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production
por: Fiorillo, Marco, et al.
Publicado: (2020)

Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells
por: Fiorillo, Marco, et al.
Publicado: (2016)

Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity
por: Sánchez-Alvarez, Rosa, et al.
Publicado: (2020)

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy
por: Fiorillo, Marco, et al.
Publicado: (2018)

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
por: Lamb, Rebecca, et al.
Publicado: (2015)

Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy
por: Lamb, Rebecca, et al.
Publicado: (2015)

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase
por: Fiorillo, Marco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c17gp038puke2he9olirkjeon5